Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CAON
MCID: NPH091
MIFTS: 54

Nephrolithiasis, Calcium Oxalate (CAON)

Categories: Blood diseases, Genetic diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nephrolithiasis, Calcium Oxalate

About this section

MalaCards integrated aliases for Nephrolithiasis, Calcium Oxalate:

Name: Nephrolithiasis, Calcium Oxalate 58 76 41 74
Kidney Stones 58 26 76 44 64
Calcium Oxalate Urolithiasis 76 30 6 17
Urolithiasis, Calcium Oxalate 58 76
Nephrolithiasis 26 74
Kidney Calculi 26 74
Urinary Stones 26 56
Kidney Stone 26 17
Urolithiasis 26 56
Caon 58 76
Calcium Oxalate Nephrolithiasis 38
Calculus of Kidney 26
Calculus, Kidney 26
Calculus, Renal 26
Renal Lithiasis 26
Renal Calculus 26
Renal Calculi 26
Renal Stones 26
Renal Stone 56
Nephrolith 26

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive

Miscellaneous:
onset in childhood
one patient has been reported (last curated june 2016)


HPO:

33
nephrolithiasis, calcium oxalate:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


Sources

Summaries for Nephrolithiasis, Calcium Oxalate

About this section
PubMed Health : 64 About kidney stones: Kidney stones are small, hard deposits that can form in a part of the kidney called the renal pelvis. Kidney stones that enter a ureter are sometimes referred to as ureteral stones. The ureters are the tubes that carry urine from the kidneys to the bladder.Many of these stones are so small that they are able to travel to the bladder in just a few days or weeks without any treatment, and then exit the body in your urine. So if the stones are smaller, it's often enough to take painkillers, drink plenty of fluids and simply wait for the kidney stones to pass through. Muscle-relaxing medications can be used to help pass medium-sized stones.Larger stones may get stuck as they exit the renal pelvis or take longer to move through the ureter, causing severe pain and other symptoms. Then they usually need to be broken up by sound waves or surgically removed. The most suitable treatment will depend on the size, the type and the position of the stones in the kidney or the urinary tract.It's common to have kidney stones multiple times. Finding the cause is a necessary part of preventing that from happening.

MalaCards based summary : Nephrolithiasis, Calcium Oxalate, also known as kidney stones, is related to xanthinuria, type i and gout, and has symptoms including renal pain An important gene associated with Nephrolithiasis, Calcium Oxalate is SLC26A1 (Solute Carrier Family 26 Member 1). The drugs Mirabegron and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and testes, and related phenotypes are acute kidney injury and ureteropelvic junction obstruction

Genetics Home Reference : 26 Kidney stones (also called renal stones or urinary stones) are small, hard deposits that form in one or both kidneys; the stones are made up of minerals or other compounds found in urine. Kidney stones vary in size, shape, and color. To be cleared from the body (or "passed"), the stones need to travel through ducts that carry urine from the kidneys to the bladder (ureters) and be excreted. Depending on their size, kidney stones generally take days to weeks to pass out of the body.

OMIM : 58 Kleta (2006) reviewed aspects of renal stone disease. Nephrolithiasis and urolithiasis remain major public health problems of largely unknown cause. While disorders such as cystinuria (220100) and primary hyperoxaluria (see 259900) that have nephrolithiasis as a major feature have advanced understanding of the metabolic and physiologic processes of stone formation in general, they have not addressed the etiology of calcium oxalate stone formation, responsible for approximately 75% of urolithiasis cases in humans. Men are affected twice as often as women, but children show no such gender bias. The recurrence rate is also high. In populations of European ancestry, 5 to 10% of adults experience the painful precipitation of calcium oxalate in their urinary tracts. Thorleifsson et al. (2009) noted that between 35 and 65% of hypercalciuric stone formers and up to 70% of subjects with hypercalciuria have relatives with nephrolithiasis, and twin studies have estimated the heritability of kidney stones to be 56%. (167030)

MedlinePlus : 44 A kidney stone is a solid piece of material that forms in the kidney from substances in the urine. It may be as small as a grain of sand or as large as a pearl. Most kidney stones pass out of the body without help from a doctor. But sometimes a stone will not go away. It may get stuck in the urinary tract, block the flow of urine and cause great pain. The following may be signs of kidney stones that need a doctor's help: Extreme pain in your back or side that will not go away Blood in your urine Fever and chills Vomiting Urine that smells bad or looks cloudy A burning feeling when you urinate Your doctor will diagnose a kidney stone with urine, blood, and imaging tests. If you have a stone that won't pass on its own, you may need treatment. It can be done with shock waves; with a scope inserted through the tube that carries urine out of the body, called the urethra; or with surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

UniProtKB/Swiss-Prot : 76 Nephrolithiasis, calcium oxalate: A form of nephrolithiasis, a condition in which urinary supersaturation leads to stone formation in the urinary system. Patients manifest acute renal colic with severe pain originating in the flank. Patients with small, non-obstructing stones or those with staghorn calculi may be asymptomatic. The majority of renal calculi contain calcium. CAON is characterized by calcium oxalate kidney stones.

Wikipedia : 77 Kidney stone disease, also known as urolithiasis, is when a solid piece of material (kidney stone)... more...

Sources

Related Diseases for Nephrolithiasis, Calcium Oxalate

About this section

Diseases related to Nephrolithiasis, Calcium Oxalate via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 391)
# Related Disease Score Top Affiliating Genes
1 xanthinuria, type i 31.5 AGXT APRT SPP1 UMOD
2 gout 31.3 APRT UMOD
3 nephrolithiasis 31.1 AGXT APRT SLC26A1 SPP1 UMOD
4 nephrocalcinosis 31.1 AGXT SPP1 UMOD
5 chronic kidney failure 31.0 AGXT SPP1 UMOD
6 interstitial nephritis 29.2 APRT UMOD
7 nephrolithiasis, x-linked recessive, with renal failure 12.6
8 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.6
9 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.5
10 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.0
11 xanthinuria, type ii 11.6
12 hyperglycinuria 11.5
13 dent disease 1 11.5
14 hyperparathyroidism 2 with jaw tumors 11.5
15 hypouricemia, renal, 1 11.5
16 hyperparathyroidism 11.4
17 primary hyperparathyroidism 11.4
18 renal tubular acidosis, distal 11.4
19 horseshoe kidney 11.4
20 hypercalciuria, absorptive, 2 11.3
21 alkaptonuria 11.3
22 nephrolithiasis, uric acid 11.3
23 ureterolithiasis 11.3
24 urethral calculus 11.3
25 medullary sponge kidney 11.3
26 hyperoxaluria, primary, type i 11.2
27 renal tubular acidosis, distal, with progressive nerve deafness 11.2
28 hypocalcemia, autosomal dominant 1 11.2
29 renal tubular acidosis, distal, autosomal dominant 11.1
30 hypotonia-cystinuria syndrome 11.1
31 renal tubular acidosis, distal, with hemolytic anemia 11.1
32 hypouricemia, renal, 2 11.1
33 urolithiasis, uric acid, autosomal dominant 11.0
34 acute urate nephropathy 11.0
35 urate oxidase, pseudogene 11.0
36 5-oxoprolinase deficiency 11.0
37 kelley-seegmiller syndrome 11.0
38 phosphoribosylpyrophosphate synthetase superactivity 11.0
39 multiple endocrine neoplasia, type i 11.0
40 hypomagnesemia 3, renal 11.0
41 hyperoxaluria, primary, type ii 11.0
42 dent disease 2 11.0
43 glucose/galactose malabsorption 11.0
44 hyperoxaluria, primary, type iii 11.0
45 adenine phosphoribosyltransferase deficiency 11.0
46 congenital short bowel syndrome 11.0
47 hypocalcemia, autosomal dominant 2 11.0
48 short bowel syndrome 11.0
49 hypoparathyroidism 11.0
50 anuria 11.0

Graphical network of the top 20 diseases related to Nephrolithiasis, Calcium Oxalate:



Diseases related to Nephrolithiasis, Calcium Oxalate
Sources

Symptoms & Phenotypes for Nephrolithiasis, Calcium Oxalate

About this section

Human phenotypes related to Nephrolithiasis, Calcium Oxalate:

33
# Description HPO Frequency HPO Source Accession
1 acute kidney injury 33 HP:0001919
2 ureteropelvic junction obstruction 33 HP:0000074
3 hyperoxaluria 33 HP:0003159
4 calcium oxalate nephrolithiasis 33 HP:0008672

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Bladder:
ureteropelvic junction obstruction

Laboratory Abnormalities:
increased urinary oxalate

Genitourinary Kidneys:
acute renal failure
nephrolithiasis, calcium oxalate

Clinical features from OMIM:

167030

UMLS symptoms related to Nephrolithiasis, Calcium Oxalate:


renal pain

MGI Mouse Phenotypes related to Nephrolithiasis, Calcium Oxalate:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.35 AGXT APRT SLC26A1 SPP1 UMOD
2 renal/urinary system MP:0005367 9.02 AGXT APRT SLC26A1 SPP1 UMOD
Sources

Drugs & Therapeutics for Nephrolithiasis, Calcium Oxalate

About this section

PubMedHealth treatment related to Nephrolithiasis, Calcium Oxalate: 64

If you have smaller kidney stones that aren't painful, all you need to do is wait to pass them when you urinate. It's possible to tell by their size and location whether they can pass on their own. You can use painkillers such as diclofenac, ibuprofen or metamizole to relieve any pain. They can be combined with stronger drugs (opioids) for more severe pain.Certain muscle-relaxing medications (alpha blockers) can make it easier to pass kidney stones that are 5 to 10 millimeters in diameter. Larger kidney stones usually need to be removed. Depending on how large the kidney stones are and where they're located, sound waves can be used to destroy them or they can be removed using endoscopy or surgery.

Drugs for Nephrolithiasis, Calcium Oxalate (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 356)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mirabegron Approved Phase 4 223673-61-8 9865528
2
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
3
Tamsulosin Approved, Investigational Phase 4,Phase 3,Not Applicable 106133-20-4 129211
4
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 74103-06-3, 66635-83-4 3826
5
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
6
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
7
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
8
tannic acid Approved Phase 4,Not Applicable 1401-55-4
9
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable
10
Allopurinol Approved Phase 4,Phase 2,Phase 1 315-30-0 2094
11
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
12
Opium Approved, Illicit Phase 4 8008-60-4
13
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
14
Belladonna Approved, Experimental Phase 4
15
Scopolamine Approved, Investigational Phase 4,Phase 3 51-34-3, 6533-68-2 5184
16
Loperamide Approved Phase 4 53179-11-6 3955
17
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
21
Losartan Approved Phase 4 114798-26-4 3961
22
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
23
Verapamil Approved Phase 4 52-53-9 2520
24
Selenium Approved, Investigational, Vet_approved Phase 4,Not Applicable 7782-49-2
25
Remifentanil Approved Phase 4 132875-61-7 60815
26
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
27
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 38396-39-3, 2180-92-9 2474
28
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
29
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
30
Pentazocine Approved, Vet_approved Phase 4 359-83-1 441278
31
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
32
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
33
Ondansetron Approved Phase 4 99614-02-5 4595
34
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
35
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
36
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
37
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
38
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
39
leucovorin Approved Phase 4,Phase 1,Not Applicable 58-05-9 143 6006
40
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
41
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
42
Cephalexin Approved, Investigational, Vet_approved Phase 4,Not Applicable 15686-71-2 27447
43
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
44
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
45
Nitrofurantoin Approved, Vet_approved Phase 4,Not Applicable 67-20-9 5353830
46
Tranexamic Acid Approved Phase 4 1197-18-8 5526
47
Ampicillin Approved, Vet_approved Phase 4,Not Applicable 69-53-4 6249
48
Vancomycin Approved Phase 4 1404-90-6 14969 441141
49
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
50
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 381)
# Name Status NCT ID Phase Drugs
1 Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS Unknown status NCT02451319 Phase 4
2 Comparison of Safety and Efficiency of 20w and 30w Holmium Laser Device in Management of 2-3 cm Diameter Kidney Stones With Retrograde Intrarenal Surgery Unknown status NCT02443909 Phase 4
3 Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study) Unknown status NCT02489656 Phase 4
4 Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones Unknown status NCT02430168 Phase 4
5 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
6 Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery? Unknown status NCT02430883 Phase 4
7 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
8 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
9 Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis Completed NCT01329042 Phase 4 Potassium-sodium citrate
10 The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation Completed NCT02373384 Phase 4 Oral alkalinization (Potassium citrate, Allopurinol)
11 Vitamin D Repletion in Stone Formers With Hypercalciuria Completed NCT01295879 Phase 4 Ergocalciferol
12 Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy Completed NCT00765128 Phase 4 Ketorolac;Placebo
13 The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain Completed NCT03332056 Phase 4 Belladonna and Opium
14 Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management Completed NCT02187614 Phase 4 Diclofenac;Morphine;Paracetamol;Placebos
15 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy Completed NCT02818140 Phase 4 Ropivacaine;Saline
16 Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? Completed NCT01675362 Phase 4 Antioxidant group;Calcium Channel Blockers;Angiotensin receptor blocker group;Placebo
17 Remifentanil in Extracorporeal Shock Wave Lithotripsy Completed NCT01452880 Phase 4 Remifentanil;Remifentanil
18 Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic Completed NCT00310908 Phase 4 Tramadol Hcl
19 Study of Tomography of Nephrolithiasis Evaluation Completed NCT01451931 Phase 4
20 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
21 Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Nephrolithotomy Operations in Children Completed NCT02291692 Phase 4
22 Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL Completed NCT02878512 Phase 4
23 The Comparison of Low Thoracic Paravertebral Block Versus Peritubal Infiltration Completed NCT02764008 Phase 4 Bupivacaine
24 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Completed NCT01381120 Phase 4 Solifenacin succinate treatment;Oxycodone and acetaminophen combination treatment
25 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4 Bisphosphonate treatment
26 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
27 VITamine D Supplementation in RenAL Transplant Recipients - VITALE Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
28 Struvite Stones Antibiotic Study Recruiting NCT02375295 Phase 4 ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
29 Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy Recruiting NCT02966236 Phase 4 Tranexamic Acid;Placebos
30 Study of Ketorolac Versus Opioid for Pain After Endoscopy Recruiting NCT03888144 Phase 4 Oxycodone;Ketorolac
31 Antibiotic Prophylaxis Before Shock Wave Lithotripsy Recruiting NCT03692715 Phase 4 Ciprofloxacin;Placebo
32 Alkalinization by Urologists & Nephrologists Recruiting NCT03035812 Phase 4 Alkali
33 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Active, not recruiting NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
34 Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment Enrolling by invitation NCT03229889 Phase 4 Cialis 5Mg Tablet;Flomax 0.4Mg Capsule;Placebo
35 Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
36 Opioid Free Management After Ureteroscopy Not yet recruiting NCT03872843 Phase 4 Norco 5milligram-325milligram Tablet;Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
37 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
38 Trial of High Dose Vitamin D in Patient's With Crohn's Disease Terminated NCT02208310 Phase 4 Cholecalciferol 10,000 IU;Cholecalciferol 400 IU
39 Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Terminated NCT00199524 Phase 4
40 The Use of Intranasal Ketoralac for Pain Management Terminated NCT01736358 Phase 4 Intranasal Ketoralac;Placebo
41 A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Terminated NCT03226899 Phase 4 Lesinurad;XOI;Placebo
42 Pre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain Withdrawn NCT03549611 Phase 4 Multimodal Oral Drug Regimen;Acetaminophen
43 Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus Unknown status NCT01215708 Phase 3 Tamsulosin
44 Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney Unknown status NCT00959153 Phase 3
45 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
46 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
47 Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL Completed NCT00784472 Phase 3 oxycodone;morphine
48 Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis Completed NCT01022060 Phase 3
49 Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract Completed NCT00428428 Phase 2, Phase 3 Isoproterenol
50 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3

Search NIH Clinical Center for Nephrolithiasis, Calcium Oxalate

Sources

Genetic Tests for Nephrolithiasis, Calcium Oxalate

About this section

Genetic tests related to Nephrolithiasis, Calcium Oxalate:

# Genetic test Affiliating Genes
1 Calcium Oxalate Urolithiasis 30 SLC26A1
Sources

Anatomical Context for Nephrolithiasis, Calcium Oxalate

About this section

MalaCards organs/tissues related to Nephrolithiasis, Calcium Oxalate:

42
Kidney, Bone, Testes, Prostate, Colon, Spinal Cord, Brain
Sources

Publications for Nephrolithiasis, Calcium Oxalate

About this section

Articles related to Nephrolithiasis, Calcium Oxalate:

(show top 50) (show all 853)
# Title Authors Year
1
Kidney Stones and Risk of Osteoporotic Fracture in Chronic Kidney Disease. ( 30760766 )
2019
2
Recurrent kidney stones in a child with Lesch-Nyhan syndrome: Questions. ( 30112653 )
2019
3
Recurrent kidney stones in a child with Lesch-Nyhan syndrome: Answers. ( 30112657 )
2019
4
Re: Incomplete Distal Renal Tubular Acidosis and Kidney Stones. ( 30759664 )
2019
5
Vitamin D and calcium kidney stones: a review and a proposal. ( 30136085 )
2019
6
Gastrin-releasing peptide receptor gene silencing inhibits the development of the epithelial-mesenchymal transition and formation of a calcium oxalate crystal in renal tubular epithelial cells in mice with kidney stones via the PI3K/Akt signaling pathway. ( 30144073 )
2019
7
Comparison of miniaturized percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for the treatment of large kidney stones: a randomized prospective study. ( 29858913 )
2019
8
In vitro feasibility of next generation non-linear beamforming ultrasound methods to characterize and size kidney stones. ( 29356874 )
2019
9
An easy risk stratification to recommend the optimal patients with 2-3 cm kidney stones to receive retrograde intrarenal surgery or mini-percutaneous nephrolithotomy. ( 31101948 )
2019
10
Fluid Intake and Dietary Factors and the Risk of Incident Kidney Stones in UK Biobank: A Population-based Prospective Cohort Study. ( 31085062 )
2019
11
New-onset Metabolic Risk Factors and the Incidence of Kidney Stones: A Prospective Cohort Study. ( 31077518 )
2019
12
Retrograde intrarenal surgery technique without using fluoroscopy and access sheet in the treatment of kidney stones ( 31064167 )
2019
13
Progress and prospects in the management of kidney stones and developments in phyto-therapeutic modalities. ( 31046493 )
2019
14
The Durability of Active Surveillance in Patients with Asymptomatic Kidney Stones: A Systematic Review. ( 31044612 )
2019
15
Followup Care after Emergency Department Visits for Kidney Stones: A Missed Opportunity. ( 31032386 )
2019
16
Re: The Impact of Dust and Confinement on Fragmentation of Kidney Stones by Shockwave Lithotripsy in Tissue Phantoms. ( 31009985 )
2019
17
Kidney Stones: Treatment and Prevention. ( 30990297 )
2019
18
Innovations in Ultrasound Technology in the Management of Kidney Stones. ( 30961860 )
2019
19
Re: Disproportionate Use of Inpatient Care by Older Adults with Kidney Stones. ( 30932772 )
2019
20
Re: SIRT3 Inhibited the Formation of Calcium Oxalate-Induced Kidney Stones through Regulating NRF2/HO-1 Signaling Pathway. ( 30925129 )
2019
21
Thulium fiber laser ablation of kidney stones using an automated, vibrating fiber. ( 30915783 )
2019
22
Morphological characteristics and microstructure of kidney stones using synchrotron radiation μCT reveal the mechanism of crystal growth and aggregation in mixed stones. ( 30901364 )
2019
23
Paracellular calcium transport in the proximal tubule and the formation of kidney stones. ( 30838875 )
2019
24
Kidney Stones and Risk of Narcotic Use. ( 30829133 )
2019
25
Editorial comment on END-2018-0516-OR.R1. ( 30808186 )
2019
26
Comparison of tubeless percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for kidney stones: A meta-analysis of randomized trials. ( 30782495 )
2019
27
Differentiating kidney stones from phleboliths in unenhanced low-dose computed tomography using radiomics and machine learning. ( 30747299 )
2019
28
Meeting report of the "Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017". ( 30680550 )
2019
29
Mineralogical, compositional and isotope characterization of human kidney stones (urolithiasis) in a Sri Lankan population. ( 30671690 )
2019
30
Re: Hyponatremia and the Risk of Kidney Stones: A Matched Case-Control Study in a Large U.S. Health System. ( 30653007 )
2019
31
Re: Geobiology Reveals how Human Kidney Stones Dissolve In Vivo. ( 30653006 )
2019
32
Re: Variation in National Opioid Prescribing Patterns following Surgery for Kidney Stones. ( 30653004 )
2019
33
High power holmium:YAG versus thulium fiber laser treatment of kidney stones in dusting mode: ablation rate and fragment size studies. ( 30648761 )
2019
34
Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones. ( 30607567 )
2019
35
Vitamin D and kidney stones - is there an association? ( 30576591 )
2019
36
Re: Geobiology Reveals How Human Kidney Stones Dissolve In Vivo. ( 30449699 )
2019
37
Green tea intake and risk of incident kidney stones: Prospective cohort studies in middle-aged and elderly Chinese individuals. ( 30408844 )
2019
38
Ascorbic Acid Supplements and Kidney Stones Incidence Among Men and Women: A systematic review and meta-analysis. ( 30178451 )
2019
39
Liver transplant, toxoplasmosis and kidney stones: connecting the dots. ( 30772835 )
2019
40
Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva. ( 29241827 )
2018
41
Different managements of horseshoe kidney stones, any difference in the outcome? ( 30089987 )
2018
42
Incidence and characteristics of kidney stones in patients with horseshoe kidney: A systematic review and meta-analysis. ( 29416282 )
2018
43
Timely Evaluation and Management of Primary Hyperparathyroidism in Patients With Kidney Stones. ( 30463775 )
2018
44
Controversies in kidney stones and other chronic kidney disease topics. ( 30585853 )
2018
45
Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study. ( 30563989 )
2018
46
Impact of patient position on the outcomes of percutaneous neprolithotomy for complex kidney stones. ( 30088725 )
2018
47
Development of a personalized diagnostic model for kidney stone disease tailored to acute care by integrating large clinical, demographics and laboratory data: the diagnostic acute care algorithm - kidney stones (DACA-KS). ( 30119627 )
2018
48
Comparison of Retrograde Intrarenal Surgery and Percutaneous Nephrolithotomy Methods For Management of Big- Sized Kidney Stones(? 4 cm): Single Center Retrospective Study. ( 30120766 )
2018
49
Protective effect of dietary polyphenol caffeic acid on ethylene glycol-induced kidney stones in rats. ( 28616648 )
2018
50
Vitamin B6 intake and the risk of incident kidney stones. ( 28674784 )
2018
Sources

Variations for Nephrolithiasis, Calcium Oxalate

About this section

UniProtKB/Swiss-Prot genetic disease variations for Nephrolithiasis, Calcium Oxalate:

76
# Symbol AA change Variation ID SNP ID
1 SLC26A1 p.Thr185Met VAR_077135 rs139024319
2 SLC26A1 p.Ser358Leu VAR_077136 rs148832260

ClinVar genetic disease variations for Nephrolithiasis, Calcium Oxalate:

6 (show top 50) (show all 82)
# Gene Variation Type Significance SNP ID Assembly Location
1 CD44 NM_000610.3(CD44): c.67+11205G> A single nucleotide variant association rs353623 GRCh37 Chromosome 11, 35172122: 35172122
2 CD44 NM_000610.3(CD44): c.68-5843A> G single nucleotide variant association rs3794109 GRCh38 Chromosome 11, 35170732: 35170732
3 CD44 NM_000610.3(CD44): c.68-5843A> G single nucleotide variant association rs3794109 GRCh37 Chromosome 11, 35192279: 35192279
4 BGLAP NM_199173.5(BGLAP): c.*304G> A single nucleotide variant association rs759330 NCBI36 Chromosome 1, 154479881: 154479881
5 BGLAP NM_199173.5(BGLAP): c.*304G> A single nucleotide variant association rs759330 GRCh37 Chromosome 1, 156213257: 156213257
6 BGLAP NM_199173.5(BGLAP): c.*304G> A single nucleotide variant association rs759330 GRCh38 Chromosome 1, 156243466: 156243466
7 AHSG NM_001622.3(AHSG): c.574-298T> G single nucleotide variant association rs2070634 NCBI36 Chromosome 3, 187818721: 187818721
8 AHSG NM_001622.3(AHSG): c.574-298T> G single nucleotide variant association rs2070634 GRCh37 Chromosome 3, 186336027: 186336027
9 AHSG NM_001622.3(AHSG): c.574-298T> G single nucleotide variant association rs2070634 GRCh38 Chromosome 3, 186618238: 186618238
10 AHSG NM_001622.3(AHSG): c.574-149A> G single nucleotide variant association rs2070635 NCBI36 Chromosome 3, 187818870: 187818870
11 AHSG NM_001622.3(AHSG): c.574-149A> G single nucleotide variant association rs2070635 GRCh37 Chromosome 3, 186336176: 186336176
12 AHSG NM_001622.3(AHSG): c.574-149A> G single nucleotide variant association rs2070635 GRCh38 Chromosome 3, 186618387: 186618387
13 CD44 NM_000610.3(CD44): c.67+11205G> A single nucleotide variant association rs353623 NCBI36 Chromosome 11, 35128698: 35128698
14 CD44 NM_000610.3(CD44): c.67+11205G> A single nucleotide variant association rs353623 GRCh38 Chromosome 11, 35150575: 35150575
15 CD44 NM_000610.3(CD44): c.67+14128T> C single nucleotide variant association rs353618 NCBI36 Chromosome 11, 35131621: 35131621
16 CD44 NM_000610.3(CD44): c.67+14128T> C single nucleotide variant association rs353618 GRCh38 Chromosome 11, 35153498: 35153498
17 CD44 NM_000610.3(CD44): c.67+14128T> C single nucleotide variant association rs353618 GRCh37 Chromosome 11, 35175045: 35175045
18 CD44 NM_000610.3(CD44): c.68-18471G> A single nucleotide variant association rs353612 NCBI36 Chromosome 11, 35136227: 35136227
19 CD44 NM_000610.3(CD44): c.68-18471G> A single nucleotide variant association rs353612 GRCh38 Chromosome 11, 35158104: 35158104
20 CD44 NM_000610.3(CD44): c.68-18471G> A single nucleotide variant association rs353612 GRCh37 Chromosome 11, 35179651: 35179651
21 CD44 NM_000610.3(CD44): c.68-13570A> T single nucleotide variant association rs353637 NCBI36 Chromosome 11, 35141128: 35141128
22 CD44 NM_000610.3(CD44): c.68-13570A> T single nucleotide variant association rs353637 GRCh38 Chromosome 11, 35163005: 35163005
23 CD44 NM_000610.3(CD44): c.68-13570A> T single nucleotide variant association rs353637 GRCh37 Chromosome 11, 35184552: 35184552
24 CD44 NM_000610.3(CD44): c.68-9931G> A single nucleotide variant association rs353630 NCBI36 Chromosome 11, 35144767: 35144767
25 CD44 NM_000610.3(CD44): c.68-9931G> A single nucleotide variant association rs353630 GRCh38 Chromosome 11, 35166644: 35166644
26 CD44 NM_000610.3(CD44): c.68-9931G> A single nucleotide variant association rs353630 GRCh37 Chromosome 11, 35188191: 35188191
27 CD44 NM_000610.3(CD44): c.68-6677C> G single nucleotide variant association rs353647 NCBI36 Chromosome 11, 35148021: 35148021
28 CD44 NM_000610.3(CD44): c.68-6677C> G single nucleotide variant association rs353647 GRCh38 Chromosome 11, 35169898: 35169898
29 CD44 NM_000610.3(CD44): c.68-6677C> G single nucleotide variant association rs353647 GRCh37 Chromosome 11, 35191445: 35191445
30 CD44 NM_000610.3(CD44): c.68-5908G> A single nucleotide variant association rs3794110 NCBI36 Chromosome 11, 35148790: 35148790
31 CD44 NM_000610.3(CD44): c.68-5908G> A single nucleotide variant association rs3794110 GRCh38 Chromosome 11, 35170667: 35170667
32 CD44 NM_000610.3(CD44): c.68-5908G> A single nucleotide variant association rs3794110 GRCh37 Chromosome 11, 35192214: 35192214
33 CD44 NM_000610.3(CD44): c.68-5843A> G single nucleotide variant association rs3794109 NCBI36 Chromosome 11, 35148855: 35148855
34 CD44 NM_000610.3(CD44): c.68-5493C> T single nucleotide variant association rs112762 NCBI36 Chromosome 11, 35149205: 35149205
35 CD44 NM_000610.3(CD44): c.68-5493C> T single nucleotide variant association rs112762 GRCh38 Chromosome 11, 35171082: 35171082
36 CD44 NM_000610.3(CD44): c.68-5493C> T single nucleotide variant association rs112762 GRCh37 Chromosome 11, 35192629: 35192629
37 CD44 NM_000610.3(CD44): c.234-905G> A single nucleotide variant association rs3794105 NCBI36 Chromosome 11, 35157492: 35157492
38 CD44 NM_000610.3(CD44): c.234-905G> A single nucleotide variant association rs3794105 GRCh38 Chromosome 11, 35179369: 35179369
39 CD44 NM_000610.3(CD44): c.234-905G> A single nucleotide variant association rs3794105 GRCh37 Chromosome 11, 35200916: 35200916
40 CD44 NM_000610.3(CD44): c.923-767T> A single nucleotide variant association rs7110737 NCBI36 Chromosome 11, 35178438: 35178438
41 CD44 NM_000610.3(CD44): c.923-767T> A single nucleotide variant association rs7110737 GRCh38 Chromosome 11, 35200315: 35200315
42 CD44 NM_000610.3(CD44): c.923-767T> A single nucleotide variant association rs7110737 GRCh37 Chromosome 11, 35221862: 35221862
43 CD44 NM_000610.3(CD44): c.2024+779A> G single nucleotide variant association rs7116432 NCBI36 Chromosome 11, 35200634: 35200634
44 CD44 NM_000610.3(CD44): c.2024+779A> G single nucleotide variant association rs7116432 GRCh38 Chromosome 11, 35222511: 35222511
45 CD44 NM_000610.3(CD44): c.2024+779A> G single nucleotide variant association rs7116432 GRCh37 Chromosome 11, 35244058: 35244058
46 HAO1 NM_017545.2(HAO1): c.*697T> C single nucleotide variant association rs6055363 NCBI36 Chromosome 20, 7811543: 7811543
47 HAO1 NM_017545.2(HAO1): c.*697T> C single nucleotide variant association rs6055363 GRCh37 Chromosome 20, 7863543: 7863543
48 HAO1 NM_017545.2(HAO1): c.*697T> C single nucleotide variant association rs6055363 GRCh38 Chromosome 20, 7882896: 7882896
49 HAO1 NM_017545.2(HAO1): c.814-2945A> G single nucleotide variant association rs2294305 NCBI36 Chromosome 20, 7817456: 7817456
50 HAO1 NM_017545.2(HAO1): c.814-2945A> G single nucleotide variant association rs2294305 GRCh37 Chromosome 20, 7869456: 7869456
Sources

Expression for Nephrolithiasis, Calcium Oxalate

About this section
Search GEO for disease gene expression data for Nephrolithiasis, Calcium Oxalate.
Sources

Pathways for Nephrolithiasis, Calcium Oxalate

About this section
Sources

GO Terms for Nephrolithiasis, Calcium Oxalate

About this section

Cellular components related to Nephrolithiasis, Calcium Oxalate according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 8.62 SLC26A1 UMOD
Sources

Sources for Nephrolithiasis, Calcium Oxalate

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....